Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01623167|
Recruitment Status : Recruiting
First Posted : June 19, 2012
Last Update Posted : May 9, 2018
- Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which suppress the immune system and stop it from attacking the bone marrow. However, this treatment does not work in all people. Some people still have poor blood cell counts even after treatment.
- Eltrombopag is a drug designed to mimic a protein in the body called thrombopoietin. It helps the body to make more platelets. It may also cause the body to make more red and white blood cells. Studies have shown that eltrombopag may be useful when added to standard treatment for severe aplastic anemia. It may help improve poor blood cell counts.
- To test the safety and effectiveness of adding eltrombopag to standard immunosuppressive therapy for severe aplastic anemia.
- Individuals at least 2 years of age who have severe aplastic anemia that has not yet been treated.
- Participants will be screened with a physical exam, medical history, and blood tests. Blood and urine samples will be collected.
- Participants will start treatment with horse-ATG and cyclosporine. Treatment will be given according to the standard of care for the disease.
- Cohort 1: After 14 days, participants will start taking eltrombopag. They will take eltrombopag for up to 6 months.
- Cohort 2: After 14 days, participants will start taking eltrombopag. They will take eltrombopag for up to 3 months.
- Cohort 3 and Extension Cohort: Participants will start taking eltrombopag on Day 1. They will take eltrombopag for up to 6 months.
- Participants may receive other medications to prevent infections during treatment.
- Treatment will be monitored with frequent blood tests. Participants will also fill out questionnaires about their symptoms and their quality of life.
|Condition or disease||Intervention/treatment||Phase|
|Aplastic Anemia Neutropenia Pancytopenia Anemia Thrombocytopenia||Drug: Eltrombopag Drug: Horse Anti-Thymocyte Globulin (ATG) Drug: Cyclosporine A (CSA)||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||182 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia|
|Study Start Date :||June 12, 2012|
|Estimated Primary Completion Date :||January 30, 2019|
|Estimated Study Completion Date :||January 30, 2024|
U.S. FDA Resources
- The primary endpoint will be the rate of complete hematologic response at six months.
- Secondary endpoints are relapse, robust hematologic blood count recovery at 3, 6, and 12 months, survival, clonal evolution to myelodysplasia and leukemia, and marrow stem cell content.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623167
|Contact: Olga J Rios, R.N.||(301) email@example.com|
|Contact: Neal S Young, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Neal S Young, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|